Travatan and Lumigan Join Prostaglandin Class With March 16 Approval
Executive Summary
Alcon's Travatan (travoprost) and Allergan's Lumigan (bimatoprost) are entering the prostaglandin analog class of glaucoma therapies following simultaneous approvals March 16.